Novo Nordisk Accuses Telehealth Company Hims of 'Deceptive Marketing' and Ends Wegovy Partnership

Novo Nordisk’s Wegovy, the blockbuster weight loss drug, debuts in India: How much will it cost, who needs it, key benefits

Studies have shown weight loss in users by almost 10 to 15 per cent.

Novo Nordisk accuses telehealth company Hims of 'deceptive marketing' and ends Wegovy partnership

Novo Nordisk has terminated its partnership with telehealth company Hims & Hers Health, accusing it of deceptively marketing weight-loss drugs.

Novo Nordisk launches Wegovy in India, targets obesity treatment market, offers semaglutide-based weekly injection

Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 and Rs 26,050 per month, the injectable drug targets India's large obese population. The company aims to create awareness and collaborate with stakeholders to combat obesity, citing its significant impact on India's GDP.

Novo Nordisk Launches Weight-Loss Drug 'Wegovy' In India

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy as a once-a-week injection in India.

Lilly drug saves muscle when added to Wegovy weight-loss shot

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while losing weight, offering a potential solution to one of the key problems that’s emerged with popular obesity shots.